New antiretroviral drugs

Area of Science:

• Infectious Diseases
• Pharmacology
• Virology

Background:

• Current combination antiretroviral therapy for HIV infection faces challenges including toxicity, cost, and drug resistance.
• Despite 21 approved antiretroviral drugs, limitations persist, necessitating the development of expanded therapeutic options.

Purpose of the Study:

• To review the current status of antiretroviral drugs for HIV treatment.
• To summarize novel antiretroviral drug classes in clinical development.

Main Methods:

• Literature review of existing and emerging antiretroviral agents.
• Categorization of drugs by mechanism of action (e.g., reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors).

Main Results:

• Overview of new nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and fusion inhibitors.
• Summary of emerging antiretroviral therapy classes: attachment inhibitors, chemokine receptor antagonists, integrase inhibitors, and maturation inhibitors.

Conclusions:

• Expansion of therapeutic options through reformulation, new compound discovery, and novel targets is critical for effective HIV management.
• Emerging drug classes offer potential to overcome limitations of current HIV treatment regimens.